Entourage Health (ETRGF) P/S Ratio
Entourage Health (ETRGF) has a price-to-sales ratio of 14.73x, placing it in the Expensive range for cannabis stocks. The company has a market cap of $1.74B and TTM revenue of $1.14B. Revenue is growing 22.0% YoY.
P/S Ratio (TTM)
14.73x
EV/Revenue
6.05x
Market Cap
$1.74B
Revenue Growth
+22.0%
Valuation Breakdown
| Metric | Value |
|---|---|
| Stock Price | $3.32 |
| Market Capitalization | $1.74B |
| TTM Revenue | $1.14B |
| Price-to-Sales (TTM) | 14.73x |
| EV/Revenue | 6.05x |
| Revenue Growth (YoY) | +22.0% |
| Gross Margin | 23.7% |
| Sector | LP |
| Exchange | OTC |
| Valuation Range | Expensive |
Frequently Asked Questions
What is ETRGF's current price-to-sales ratio?+
The price-to-sales (P/S) ratio divides Entourage Health's market capitalization by its trailing twelve months of revenue. Since many cannabis companies are not yet profitable, P/S is one of the most widely used valuation metrics in the sector. A lower ratio may suggest the stock is undervalued relative to revenue.
How does ETRGF's P/S compare to other cannabis stocks?+
P/S ratios in cannabis typically range from 0.5x to 5x depending on growth rate, profitability, and market sentiment. High-growth companies command higher multiples, while mature, lower-growth companies trade at lower multiples. Compare Entourage Health to peers in the same sub-sector (MSO, LP, ancillary) for meaningful context.
Is ETRGF overvalued or undervalued based on P/S?+
A single metric like P/S cannot definitively determine if Entourage Health is over- or undervalued. Consider P/S alongside revenue growth rate, gross margins, cash position, and competitive dynamics. A company growing revenue at 50% YoY may justify a higher P/S than one growing at 5%. Also consider enterprise value-to-revenue (EV/Revenue) which accounts for debt and cash.